Overview
Corporate Profile
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>
Stock Chart
Stock Quote
| (Common Stock) | |
| Exchange | (US Dollar) |
| Price | |
| Change (%) | |
| Intraday High | |
| Intraday Low | |
| Volume | |
|
|
|
Copyright Nasdaq. Minimum 15 minutes delayed.
RECENT NEWS
More >>| Date | Title | ||||
|---|---|---|---|---|---|
|
05/16/18
|
Summary ToggleClovis Oncology Announces Presentations at 2018 ASCO Annual Meeting |
Accepted abstracts highlight additional data from phase 3 ARIEL3 clinical trial, as well as trials in progress presentations of Rubraca ® (rucaparib) in multiple solid tumor settings at ASCO BOULDER, Colo. --(BUSINESS WIRE)--May 16, 2018-- Clovis Oncology, Inc. |
 |
||
|
05/09/18
|
Summary ToggleCORRECTING and REPLACING Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018 |
BOULDER, Colo. --(BUSINESS WIRE)--May 9, 2018-- Presentation and webcast time listed in first paragraph of release should read: Wednesday, May 16, 2018 at 11:20 AM local time (instead of Thursday, May 17, 2018 at 10:00 AM Pacific Time). The corrected release reads: CLOVIS ONCOLOGY TO PRESENT AT THE |
|
||
|
05/09/18
|
Summary ToggleClovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018 |
BOULDER, Colo. --(BUSINESS WIRE)--May 9, 2018-- Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2018 on Thursday, May 17, 2018 at 10:00 AM Pacific Time . |
|